Therapy to Elevate CD4 Counts in HIV-1 Disease

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

February 28, 2007

Study Completion Date

February 28, 2007

Conditions
HIV Disease
Interventions
BIOLOGICAL

alpha-1-Proteinase Inhibitor

Alpha-1-Proteinase Inhibitor was delivered I.V. A patient weighing 150 pounds was infused with approximately ½ cup containing 8.4 grams of alpha-1-Proteinase Inhibitor. Patients were admitted to hospital for infusion. The I.V. infusion was approximately 1 teaspoon/minute. Patients received weekly infusions of alpha-1-Proteinase Inhibitor for 8-12 weeks. At the time of infusion, 40ml (3 Tablespoons) of blood was collected (IRB approval #R04-003). The blood sample was used to monitor viral load, CD4 cell numbers, and alpha-1-Proteinase Inhibitor.

Trial Locations (1)

10003

Cabrini Medical Center, New York

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

CSL Behring

INDUSTRY

lead

Institute for Human Genetics and Biochemistry

OTHER

NCT01370018 - Therapy to Elevate CD4 Counts in HIV-1 Disease | Biotech Hunter | Biotech Hunter